Literature DB >> 19808995

Crofelemer, an antisecretory antidiarrheal proanthocyanidin oligomer extracted from Croton lechleri, targets two distinct intestinal chloride channels.

Lukmanee Tradtrantip1, Wan Namkung, A S Verkman.   

Abstract

Crofelemer, a purified proanthocyanidin oligomer extracted from the bark latex of Croton lechleri, is in clinical trials for secretory diarrheas of various etiologies. We investigated the antisecretory mechanism of crofelemer by determining its effect on the major apical membrane transport and signaling processes involved in intestinal fluid transport. Using cell lines and measurement procedures to isolate the effects on individual membrane transport proteins, crofelemer at 50 microM had little or no effect on the activity of epithelial Na(+) or K(+) channels or on cAMP or calcium signaling. Crofelemer inhibited the cystic fibrosis transmembrane regulator (CFTR) Cl(-) channel with maximum inhibition of approximately 60% and an IC(50) approximately 7 microM. Crofelemer action at an extracellular site on CFTR produced voltage-independent block with stabilization of the channel closed state. Crofelemer did not affect the potency of glycine hydrazide or thiazolidinone CFTR inhibitors. Crofelemer action resisted washout, with <50% reversal of CFTR inhibition after 4 h. Crofelemer was also found to strongly inhibit the intestinal calcium-activated Cl(-) channel TMEM16A by a voltage-independent inhibition mechanism with maximum inhibition >90% and IC(50) approximately 6.5 microM. The dual inhibitory action of crofelemer on two structurally unrelated prosecretory intestinal Cl(-) channels may account for its intestinal antisecretory activity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19808995      PMCID: PMC2802429          DOI: 10.1124/mol.109.061051

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  33 in total

1.  Thiazolidinone CFTR inhibitor identified by high-throughput screening blocks cholera toxin-induced intestinal fluid secretion.

Authors:  Tonghui Ma; Jay R Thiagarajah; Hong Yang; Nitin D Sonawane; Chiara Folli; Luis J V Galietta; A S Verkman
Journal:  J Clin Invest       Date:  2002-12       Impact factor: 14.808

Review 2.  Calcium-activated chloride channels.

Authors:  Criss Hartzell; Ilva Putzier; Jorge Arreola
Journal:  Annu Rev Physiol       Date:  2005       Impact factor: 19.318

3.  A novel plant-derived inhibitor of cAMP-mediated fluid and chloride secretion.

Authors:  S E Gabriel; S E Davenport; R J Steagall; V Vimal; T Carlson; E J Rozhon
Journal:  Am J Physiol       Date:  1999-01

4.  A double blind, randomized, placebo-controlled study of SP-303 (Provir) in the symptomatic treatment of acute diarrhea among travelers to Jamaica and Mexico.

Authors:  Daniel DiCesare; Herbert L DuPont; John J Mathewson; David Ashley; Francisco Martinez-Sandoval; James E Pennington; Steven B Porter
Journal:  Am J Gastroenterol       Date:  2002-10       Impact factor: 10.864

5.  Mechanisms of chloride secretion induced by thermostable direct haemolysin of Vibrio parahaemolyticus in human colonic tissue and a human intestinal epithelial cell line.

Authors:  A Takahashi; Y Sato; Y Shiomi; V V Cantarelli; T Iida; M Lee; T Honda
Journal:  J Med Microbiol       Date:  2000-09       Impact factor: 2.472

6.  Immunomodulatory activity and chemical characterisation of sangre de drago (dragon's blood) from Croton lechleri.

Authors:  Ester Risco; Felipe Ghia; Roser Vila; José Iglesias; Elida Alvarez; Salvador Cañigueral
Journal:  Planta Med       Date:  2003-09       Impact factor: 3.352

7.  Evaluation of the mutagenic, antimutagenic and antiproliferative potential of Croton lechleri (Muell. Arg.) latex.

Authors:  D Rossi; R Bruni; N Bianchi; C Chiarabelli; R Gambari; A Medici; A Lista; G Paganetto
Journal:  Phytomedicine       Date:  2003-03       Impact factor: 5.340

8.  Nanomolar CFTR inhibition by pore-occluding divalent polyethylene glycol-malonic acid hydrazides.

Authors:  N D Sonawane; Dan Zhao; Olga Zegarra-Moran; Luis J V Galietta; A S Verkman
Journal:  Chem Biol       Date:  2008-07-21

9.  Small-molecule screen identifies inhibitors of a human intestinal calcium-activated chloride channel.

Authors:  Ricardo De La Fuente; Wan Namkung; Aaron Mills; A S Verkman
Journal:  Mol Pharmacol       Date:  2007-12-14       Impact factor: 4.436

10.  Expression cloning of TMEM16A as a calcium-activated chloride channel subunit.

Authors:  Björn Christian Schroeder; Tong Cheng; Yuh Nung Jan; Lily Yeh Jan
Journal:  Cell       Date:  2008-09-19       Impact factor: 41.582

View more
  42 in total

Review 1.  Chloride channel-targeted therapy for secretory diarrheas.

Authors:  Jay R Thiagarajah; A S Verkman
Journal:  Curr Opin Pharmacol       Date:  2013-08-27       Impact factor: 5.547

2.  Rotavirus toxin NSP4 induces diarrhea by activation of TMEM16A and inhibition of Na+ absorption.

Authors:  Jiraporn Ousingsawat; Myriam Mirza; Yuemin Tian; Eleni Roussa; Rainer Schreiber; David I Cook; Karl Kunzelmann
Journal:  Pflugers Arch       Date:  2011-03-12       Impact factor: 3.657

Review 3.  Crofelemer: a review of its use in the management of non-infectious diarrhoea in adult patients with HIV/AIDS on antiretroviral therapy.

Authors:  James E Frampton
Journal:  Drugs       Date:  2013-07       Impact factor: 9.546

Review 4.  Pathogen-induced secretory diarrhea and its prevention.

Authors:  S Anand; S Mandal; P Patil; S K Tomar
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-07-29       Impact factor: 3.267

5.  Analysis of Lung Gene Expression Reveals a Role for Cl- Channels in Diisocyanate-induced Airway Eosinophilia in a Mouse Model of Asthma Pathology.

Authors:  Adam V Wisnewski; Jian Liu; Carrie A Redlich
Journal:  Am J Respir Cell Mol Biol       Date:  2020-07       Impact factor: 6.914

6.  Benzopyrimido-pyrrolo-oxazine-dione CFTR inhibitor (R)-BPO-27 for antisecretory therapy of diarrheas caused by bacterial enterotoxins.

Authors:  Onur Cil; Puay-Wah Phuan; Anne Marie Gillespie; Sujin Lee; Lukmanee Tradtrantip; Jianyi Yin; Ming Tse; Nicholas C Zachos; Ruxian Lin; Mark Donowitz; Alan S Verkman
Journal:  FASEB J       Date:  2016-11-08       Impact factor: 5.191

Review 7.  Recent advances and new perspectives in targeting CFTR for therapy of cystic fibrosis and enterotoxin-induced secretory diarrheas.

Authors:  Weiqiang Zhang; Naoaki Fujii; Anjaparavanda P Naren
Journal:  Future Med Chem       Date:  2012-03       Impact factor: 3.808

Review 8.  Safety surveillance of traditional Chinese medicine: current and future.

Authors:  Shwu-Huey Liu; Wu-Chang Chuang; Wing Lam; Zaoli Jiang; Yung-Chi Cheng
Journal:  Drug Saf       Date:  2015-02       Impact factor: 5.606

Review 9.  Designing a broad-spectrum integrative approach for cancer prevention and treatment.

Authors:  Keith I Block; Charlotte Gyllenhaal; Leroy Lowe; Amedeo Amedei; A R M Ruhul Amin; Amr Amin; Katia Aquilano; Jack Arbiser; Alexandra Arreola; Alla Arzumanyan; S Salman Ashraf; Asfar S Azmi; Fabian Benencia; Dipita Bhakta; Alan Bilsland; Anupam Bishayee; Stacy W Blain; Penny B Block; Chandra S Boosani; Thomas E Carey; Amancio Carnero; Marianeve Carotenuto; Stephanie C Casey; Mrinmay Chakrabarti; Rupesh Chaturvedi; Georgia Zhuo Chen; Helen Chen; Sophie Chen; Yi Charlie Chen; Beom K Choi; Maria Rosa Ciriolo; Helen M Coley; Andrew R Collins; Marisa Connell; Sarah Crawford; Colleen S Curran; Charlotta Dabrosin; Giovanna Damia; Santanu Dasgupta; Ralph J DeBerardinis; William K Decker; Punita Dhawan; Anna Mae E Diehl; Jin-Tang Dong; Q Ping Dou; Janice E Drew; Eyad Elkord; Bassel El-Rayes; Mark A Feitelson; Dean W Felsher; Lynnette R Ferguson; Carmela Fimognari; Gary L Firestone; Christian Frezza; Hiromasa Fujii; Mark M Fuster; Daniele Generali; Alexandros G Georgakilas; Frank Gieseler; Michael Gilbertson; Michelle F Green; Brendan Grue; Gunjan Guha; Dorota Halicka; William G Helferich; Petr Heneberg; Patricia Hentosh; Matthew D Hirschey; Lorne J Hofseth; Randall F Holcombe; Kanya Honoki; Hsue-Yin Hsu; Gloria S Huang; Lasse D Jensen; Wen G Jiang; Lee W Jones; Phillip A Karpowicz; W Nicol Keith; Sid P Kerkar; Gazala N Khan; Mahin Khatami; Young H Ko; Omer Kucuk; Rob J Kulathinal; Nagi B Kumar; Byoung S Kwon; Anne Le; Michael A Lea; Ho-Young Lee; Terry Lichtor; Liang-Tzung Lin; Jason W Locasale; Bal L Lokeshwar; Valter D Longo; Costas A Lyssiotis; Karen L MacKenzie; Meenakshi Malhotra; Maria Marino; Maria L Martinez-Chantar; Ander Matheu; Christopher Maxwell; Eoin McDonnell; Alan K Meeker; Mahya Mehrmohamadi; Kapil Mehta; Gregory A Michelotti; Ramzi M Mohammad; Sulma I Mohammed; D James Morre; Vinayak Muralidhar; Irfana Muqbil; Michael P Murphy; Ganji Purnachandra Nagaraju; Rita Nahta; Elena Niccolai; Somaira Nowsheen; Carolina Panis; Francesco Pantano; Virginia R Parslow; Graham Pawelec; Peter L Pedersen; Brad Poore; Deepak Poudyal; Satya Prakash; Mark Prince; Lizzia Raffaghello; Jeffrey C Rathmell; W Kimryn Rathmell; Swapan K Ray; Jörg Reichrath; Sarallah Rezazadeh; Domenico Ribatti; Luigi Ricciardiello; R Brooks Robey; Francis Rodier; H P Vasantha Rupasinghe; Gian Luigi Russo; Elizabeth P Ryan; Abbas K Samadi; Isidro Sanchez-Garcia; Andrew J Sanders; Daniele Santini; Malancha Sarkar; Tetsuro Sasada; Neeraj K Saxena; Rodney E Shackelford; H M C Shantha Kumara; Dipali Sharma; Dong M Shin; David Sidransky; Markus David Siegelin; Emanuela Signori; Neetu Singh; Sharanya Sivanand; Daniel Sliva; Carl Smythe; Carmela Spagnuolo; Diana M Stafforini; John Stagg; Pochi R Subbarayan; Tabetha Sundin; Wamidh H Talib; Sarah K Thompson; Phuoc T Tran; Hendrik Ungefroren; Matthew G Vander Heiden; Vasundara Venkateswaran; Dass S Vinay; Panagiotis J Vlachostergios; Zongwei Wang; Kathryn E Wellen; Richard L Whelan; Eddy S Yang; Huanjie Yang; Xujuan Yang; Paul Yaswen; Clement Yedjou; Xin Yin; Jiyue Zhu; Massimo Zollo
Journal:  Semin Cancer Biol       Date:  2015-12       Impact factor: 15.707

Review 10.  Recent advances in pharmacological treatment of irritable bowel syndrome.

Authors:  Georgia Lazaraki; Grigoris Chatzimavroudis; Panagiotis Katsinelos
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.